New drug zavicefta under Real-World watch for sepsis and kidney patients
NCT ID NCT06864585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will observe how safe and effective the antibiotic Zavicefta is when used in everyday medical practice in Japan. It includes 59 patients with sepsis (a severe blood infection) or reduced kidney function who are receiving Zavicefta for the first time. Researchers will track side effects and how well the drug works over 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can a damaged kidney change how antibiotics work?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis